Crinetics Pharmaceuticals Inc Stock News

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the

Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.

Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.

Crinetics Pharmaceuticals (CRNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could b

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript

SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, Febru

Today, we take a deeper look at Crinetics Pharmaceuticals, Inc., which has seen a significant increase in its stock price in recent months. The company's primary drug candidate, paltusotine, looks lik

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in fireside chats at the 6th Annual Evercore ISI He

Crinetics Pharmaceuticals, Inc. (CRNX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

As economic and stock market uncertainty looms, you may think at first that now is not a great time to be dabbling in speculative stocks. Yet, while the broad market may be experiencing turbulence rig

Crinetics (CRNX) surges 69.6% in a month due to encouraging results from its late-stage study, paltusotine, in patients with acromegaly who were switching from current standard-of-care treatment.

SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at th

Crinetics Pharmaceuticals' lead candidate could be commercialized soon. It'll have a hard time gaining market share quickly if it gets approved for sale.

Crinetics Pharmaceuticals announced positive late-stage trial data for its acromegaly drug this week. If approved, analysts think this oral therapy could rake in nearly half a billion in annual sales